Rallybio (RLYB) Cash & Equivalents (2020 - 2026)

Rallybio has reported Cash & Equivalents for 7 years, with the latest figure at $41.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 179.44% year-over-year to $41.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.3 million (up 179.44% YoY) and the FY2025 annual result came in at $31.4 million, up 125.66% from the prior year.
• Cash & Equivalents rose to $41.3 million in Q1 2026 per RLYB's latest filing, from $31.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $81.4 million in Q1 2022 and troughed at $9.4 million in Q2 2025.
• A 5-year average of $33.6 million and a median of $31.4 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents sank 72.34% in 2022, then soared 179.44% in 2026.
• Over 5 years, Cash & Equivalents stood at $57.0 million in 2022, then sank by 57.0% to $24.5 million in 2023, then tumbled by 43.24% to $13.9 million in 2024, then surged by 125.66% to $31.4 million in 2025, then soared by 31.63% to $41.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $41.3 million, $31.4 million, and $32.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.